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Abstract
The lack of success in target-based screening approaches to the discovery of antibacterial
agents has led to reemergence of phenotypic screening as a successful approach of identi-
fying bioactive, antibacterial compounds. A challenge though with this route is then to identi-
fy the molecular target(s) and mechanism of action of the hits. This target identification, or
deorphanization step, is often essential in further optimization and validation studies. Direct
experimental identification of the molecular target of a screening hit is often complex, pre-
cisely because the properties and specificity of the hit are not yet optimized against that tar-
get, and so many false positives are often obtained. An alternative is to use computational,
predictive, approaches to hypothesize a mechanism of action, which can then be validated
in a more directed and efficient manner. Specifically here we present experimental valida-
tion of an in silico prediction from a large-scale screen performed againstMycobacterium
tuberculosis (Mtb), the causative agent of tuberculosis. The two potent anti-tubercular com-
pounds studied in this case, belonging to the tetrahydro-1,3,5-triazin-2-amine (THT) family,
were predicted and confirmed to be an inhibitor of dihydrofolate reductase (DHFR), a known
essentialMtb gene, and already clinically validated as a drug target. Given the large num-
ber of similar screening data sets shared amongst the community, this in vitro validation of
these target predictions gives weight to computational approaches to establish the mecha-
nism of action (MoA) of novel screening hit.
Introduction
The human pathogen,Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis
(TB), an infectious disease that is widespread, infecting around one third of the world’s popula-
tion [1]. The discovery of streptomycin in 1943, and the subsequent discovery and
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optimization of other anti-tubercular drugs, such as para-aminosalicylic acid, pyrazinamide,
cycloserine and ethambutol, and the introduction of directly observed short-course chemother-
apy (DOTs) delivered initial significant patient and societal benefit. However, the recent emer-
gence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains ofMtb [2],
as well as co-infection with HIV, and extended duration of chemotherapy and diagnostic de-
lays [3], have led to the re-emergence of TB as a global health threat. The worldwide mortality
rate of TB is more than 1.4 million people per year, and it is the second leading cause of death
from a single infectious agent after HIV [1]. In 2012, around 13% of the 8.6 million people who
had developed TB were HIV-positive, and 75% of these cases were in Africa [4].
To date, a variety of methods are currently employed to identify new drug leads differentiat-
ed from previous therapies, in addition to targeting an essential process in the bacteria, such
compounds also need to overcome several specific problems associated with TB drug develop-
ment, such as the significant permeability barrier, combat MDR and XDR TB, and underlying
safety profiles when used in conjunction with other drugs, in the case of co-infection with HIV.
Additionally, commercial and regulatory aspects have not provided sufficient investor-led in-
terest in development of novelMtb drugs. This has however led to a combined effort from
worldwide academia and industry on several collaborative partnerships to find solutions to this
developing TB crisis.
High-throughput screening (HTS) is one method being used to identify new drugs from
large compound repositories [5]. In this regard, GlaxoSmithKline (GSK), has identified and re-
leased the activities and structures of a large set of anti-mycobacterials into the public domain;
these are available in the ChEMBL database [6] (https://www.ebi.ac.uk/chembl/). This dataset
consists of 776 anti-mycobacterial phenotypic hits with activity againstM. bovis BCG.
Amongst these, 177 compounds were confirmed to be active againstMtbH37Rv
(MIC< 10 μM) and also displayed low human cell-line toxicity [7]. These whole-cell hits pro-
vided a privileged set of compounds with the ability to cross the cell wall ofMtb, overcoming
one of the major challenges for orally administered TB drugs [8–10]. However, the mode of ac-
tion (MoA) of these compounds is yet to be elucidated. The identification and validation of the
molecular target(s) of a compound is a complex and yet fundamental strategy in the drug dis-
covery [11]. Consequently, it is important to develop novel, and improve on existing, methods
currently used to identify and validate targets for bioactive compounds.
Advances in integrative computational methodologies combined with chemical and geno-
mics data offers a multifaceted in silico strategy for efficient selection and prioritization of po-
tential new lead candidates in anti-TB drug discovery. Utilising chemical, biological and
genomic databases enables the development and usage of computational ligand-based and
structure-based tools in the discovery of TB targets linked to the MoA studies. Recently, che-
mogenomics, an approach that utilizes chemical space (physical and chemical properties) of
small molecules and the genomic space defined by their targeted proteins to identify ligands
for all targets and vice versa [12], Structure Space and Historical Assay Space approaches have
been used to determine the MoAs for the aforementioned published GSK phenotypic hits [13].
This initiative has paved the way to an array of computational target prediction approaches for
TB. To date, 139 compounds were predicted to target proteins belonging to diverse biochemi-
cal pathways. In addition, TB mobile, [14] platforms has been used to predict targets for these
phenotypic hits. Targets predicted from both methods include essential protein kinases and
proteins in the folate pathway, as well as ABC transporters. Although, these methods provide
valuable information on potential targets of anti-TB compounds identified in phenotypic
screens, no in vitro validation of the in silicomodeled targets has been so far reported.
We have applied two distinct ligand-based computational approaches in conjunction with a
structure-based approach (docking) to predict potential targets for an anti-TB phenotypic hit
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series. To increase likely prediction accuracy we applied a tournament of three distinct meth-
ods, which we believe complement each other. For the first time, we present the in vitro valida-
tion of these results for the predicted target-compound interactions involving theMtb
dihydrofolate reductase (DHFR).Mtb DHFR is an essential protein that catalyses the reduction
of dihydrofolate to tetrahydrofolate (THF), a co-factor in the production of thymidylate, pu-
rine bases and amino acids important for the synthesis of DNA, RNA and proteins [15,16].
There are no drugs presently in clinical use that target this enzyme forMtb, therefore this work
provides experimentally confirmed ligands for mycobacterial DHFR, which will serve as start-
ing points for further hit-to-lead optimisation. In addition, our studies present computational
and experimental approaches that can effectively characterize and prioritize phenotypic
assay hits.
Materials and Methods
Ethics Statement
All experiments were approved by EMBL-EBI, University of Birmingham, and Diseases of the
Developing World (DDW-GSK) ethical committee where required and there are no ethical is-
sues to report.
Compound preparation
A set of the 776 TCAMS-TB dataset [7] compounds was retrieved from the ChEMBL database
(https://www.ebi.ac.uk/chembl/). Using suitable protocols in Pipeline Pilot version 8.5 from
Accelrys [17], 2D coordinates for each compound were generated from their canonical
SMILES. The stereochemistry, charges (formal charges for common functional groups e.g. qua-
ternary nitrogen, nitro groups, etc. were standardized, salts and single atom fragments were re-
moved, and the largest molecular fragment was kept.
Target Prediction using Multiple Category Naive Bayesian Classifier
Model Generation and validation. ChEMBL is a database of bioactive small molecules that
contains 2D structures, calculated physical chemical properties and abstracted bioactivity data
extracted from scientific journals [18]. ChEMBL version 17 (http://www.ebi.ac.uk/ChEMBL),
contains more than 1.3 million compound entities,> 9,000 annotated targets,> 50,000 publica-
tions and more than 11.4 million reported activities. The database was queried to collate a dataset
of 698,401 human and bacterial target-ligand pairs, (covering 2,257 unique proteins in total) with
the standard activity types and values defined as IC50, EC50 or Ki 10 μM, or inhibition 50%
together with information of their experimental documentation. Retrieved targets, identified by
their Uniprot accession numbers, were proteins with target confidence scores equal to or greater
than 7. This is a score in ChEMBL that shows the level of confidence in assigning molecular tar-
get, where scores 7, 8 and 9 indicate direct assignment to protein complexes, homologous single
protein and single protein, respectively. From the retrieved SMILES of the ligands, molecular
structures were generated and standardized using a Pipeline Pilot protocol.
To increase the strength of the multiple category naïve Bayesian classifier models
(MCNBCs), the dataset was filtered and 695,902 target-ligand pairs containing 1,543 targets as-
signed to at least 10 ligands were collected. For each protein accession number, the MCNBCs
were trained on the structural features of all compounds using a Pipeline Pilot protocol, in con-
junction with the extended-connectivity fingerprints of diameter 6 (ECFP_6) [19]. These circu-
lar fingerprints are intended to identify precise atom environment sub-structural features,
limited to a maximum radius of 3 bond lengths, in a molecule and have been successfully
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utilized in similarity ligand–based virtual screening of small molecule databases [20] and in TB
target prediction [13],[21].
The efficiency of the model was determined by firstly, training a model on randomly select-
ed 80% of the compounds consisting of 1,543 proteins associated with 556,188 compounds,
and EFCP_6 fingerprints. The model was tested using 52,809 unique compounds from the re-
maining 20% of the dataset. This approach guaranteed the randomized selection of compounds
for both the training and test sets and minimized bias by presenting the model with a test set of
previously unseen compounds. Here the different categories/proteins are learned by consider-
ing the frequency of appearance of a particular sub-structural feature for their different ligands
[13,22,23]. The naïve Bayesian (NB) score is based on the Bayes rule of conditional probability
which states that for two given events A and B the probability of A occurring, given that B has
already occurred, P(A|B) is given by P(A|B) = P(B|A) P(A)/P(B) where P(A) and P(B) are
probabilities of A and B respectively [22]. The probabilities are calculated using the Laplacian-
corrected estimator. More specifically, the NB score of a target is the sum (Ptotal) of the loga-
rithm of Laplacian-corrected Bayes rule of conditional probability [P(A|Fi)] for each finger-
print feature of a compound [13]. The predicted targets are ranked based on their NB scores, in
descending order. The efficiency of the model was indicated by the calculated percentage of
compounds with correctly assigned targets reported in ranked positions 1–5.
To avoid bias through inclusion of closely related compounds to the training set, com-
pounds from randomly selected 80% articles (in which the compounds and bioactivity data
were published), were used to train a second model. This training set consisted of 1,505 pro-
teins associated to 586,928 diverse compounds. The model was tested using unique compounds
retrieved from the remaining 20% of the articles, and the set contained least 108,974 molecules.
This approach guaranteed selection of random and diverse compounds for both the training
and test sets. For each target, the total Laplacian-corrected normalised probability [13,23] for
all compound features was calculated and reported as the NB score. The predicted targets were
ranked based on their NB scores, in descending order. In both cases the efficiency of each
model was determined by calculating the percentage of compounds with correctly assigned tar-
gets reported in positions 1–5. In addition, the models were validated using “leave-one-out”
cross-validation, in which each sample was left out and a model built using the rest of the sam-
ples. The model was then used to predict targets for the left out sample.
MCNBC Target Prediction
To predict targets for the 776 anti-mycobacterial compounds, a model trained on all 695,902
target-ligand pairs from ChEMBL was built. Targets with less than 10 annotated ligands were
excluded from the training set. Predicting targets for> 1,200,000 compounds in ChEMBL ver-
sion 17 database generated the background information by calculating mean NB scores (μ) and
standard deviation (σ) for each target. The entire 776 compounds were tested against the 100%
model and NB scores for each target were calculated for each compound. For each predicted
target, standard scores (Z-score) were calculated from a statistical analysis of the NB scores for
each compound; Z-score = (X—μ)/σ where, X is the NB score of a target for a compound. The
Z-score distinguishes the compound scores for a particular target from the influence of the
background noise. The predicted targets were then filtered and compounds with positive NB
scores and Z-scores> = 1.5 were retained. Suggested targets for each compound were then
ranked using NB scores.
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Using Similarity Ensemble Approach (SEA)
SEA utilizes chemical similarity between two sets of ligands to study the pharmacological rela-
tionships between drugs. In previous work, the tool was used to predict new on- and off- tar-
gets and adverse drug reaction for known drugs that were later confirmed experimentally [24],
[25]. We have used the SEA search tool available at sea.bkslab.org, to predict targets for all 776
GSK phenotypic hits. To validate the method, the tool was used to predict targets for TB drugs
of known modes of action but for which the bioactivity data is not found in ChEMBL version
16. The anti-TB dataset was divided into smaller input files of approximately 100 compounds
represented by their SMILES strings and identifiers. Similarity search between ligand sets was
derived from ChEMBL version 16 based on EFCP_4 fingerprints. In this method the aggregate
Tanimoto similarity score, is converted, using a statistical model, to the expectation (E) value
that describes the significance of similarity between an orphan compound and a set of ligands
and hence its most likely targets [26]. In addition to predicting multiple targets from different
organisms for a given compound, SEA also predicts targets at different ligand activity levels
(10,000; 1,000; 100; 10 and 1 nM). For our purposes, the best (smallest) E-value for each target-
compound pair was acquired and predictions with expectation values less than 10–1 were
significant.
Using Structure-based approach (docking)
The ligand-based methods were here used o streamline theMtb proteins for docking calcula-
tions. The Internal Coordinate Mechanism (ICM) method developed by Molsoft L.L.C [27]
was used to generate binding modes of the small molecules in the binding pocket of selected
proteins and to estimate the strength of the protein-ligand interactions based on the ICM scor-
ing function: ΔG = ΔEIntFF + TΔSTor + α1ΔEHBond + α2ΔEHBDesol + α3ΔESolEl + α4ΔEHPhob +
α5QSize where: ΔEIntFF is change in van der Waals interactions of ligand and receptor and the
internal force-field energy of the ligand, TΔSTor is the change in free energy due to conforma-
tional entropy and weighted (α1 – α5), ΔEHBond is the hydrogen bond term, ΔEHBDesol accounts
for the disruption of hydrogen bonds with solvent, ΔESolEl is the solvation electrostatic energy
change upon binding, ΔEHPhob is the hydrophobic free energy gain and Qsize is the ligand size
correction term. The ICM scores were standardized by determining the ligand efficiency indi-
ces (LEI) (ICM score divided by the number of heavy atoms) for each docked molecule [28].
Dihydrofolate reductase (DHFR), an enzyme important in the last stage of tetrahydrofolate
biosynthesis, was identified as a potential target for the 776 phenotypic hits. The protein has
been widely studied and there are three crystal structures of the open conformation of the en-
zyme in complex [16] with cycloguanil (PDBe 4kne, 2.00Å resolution), trimethoprim (PDBe
4km2, 1.40Å resolution) and pyrimethamine (PDBe 4km0, 1.30Å resolution) in the Protein
Database in Europe (PDBe). Based on the percentile ranks reported in PDBe (http://www.ebi.
ac.uk/pdbe-srv/view/entry), these three have better crystal structure quality compared to other
structures. The coordinate files for 4kne, 4km0 and 4km2 were retrieved and the ligand coordi-
nates were saved in separate files. Using ICM-docking receptor preparation tools the three pro-
tein structures were separately prepared by deleting all water molecules, optimize hydrogen,
adding missing heavy atoms and hydrogen, and adjusting amide groups and were saved as
ICM receptor molecules. The “setup receptor” tool was used to generate receptor maps using a
grid size of 0.5Å. Similarly; the cycloguanil, trimethoprim and pyrimethamine structure files
were prepared and converted to ICMmolecules. To validate the docking calculations the three
prepared ligands were re-docked into their respective protein structures, using default ICM pa-
rameters and a thoroughness/an effort value of 2 regulated the length of the docking simulation
[29]. The generated binding conformations were compared to the crystal structure
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conformations. Cycloguanil gave the best conformation, RMSD = 0.3 Å (ICM score = -25.79)
(S1 Fig., supporting information) compared to pyrimethamine (RMSD = 1.46 Å) and tri-
methoprime (RMSD = 0.86 Å). The crystal structure of DHFR in complex with cycloguanil
(4kne) was therefore used in the production stage.
Three dimension coordinates of 776 anti-TB compounds were generated using a Pipeline
Pilot protocol and saved as mol2 files. The molecules were imported into ICM, amide bonds
were fixed, hydrogen atoms were built and the structures were converted into ICMmolecules.
The compounds were docked into 4kne using thoroughness/effort value of 2 and default ICM
parameters. The compounds were ranked on their LEI and the top 100 compounds were re-
tained for further analysis. Compounds with MIC (BCG)< 5.00 μM that were commonly pre-
dicted to inhibit DHFR or had LEI>1.00 were selected for in vitro validation.
Generation ofM. bovis BCG resistant mutants, WGS, over-expression
and MIC determination
Chemical compounds used in this work were supplied by GSK. The generation of spontaneous
resistant mutants and WGS was conducted as described in [30]. For the over-production of
ThyA and DHFR inM. bovis BCG, the corresponding genes were cloned into pMV261. The
genes were initially amplified by PCR (Phusion High-Fidelity DNA polymerase; New England
Biolabs) fromM. bovis BCG strain Pasteur genomic DNA. The oligonucleotide primers used
are shown in Table 1. The fragment sizes 0.8 kb (thyA) and 0.5 kb (dfrA) were cloned into the
pMV261 vector by exploiting the primer encoded restriction sites BamHI andHindIII (FastDi-
gest restriction endonucleases, Fermentas; T4 DNA ligase, New England Biolabs). The con-
structs were verified by DNA sequencing. The constructs, including the empty pMV261 vector
were electroporated intoM. bovis BCG and MIC values determined as described [30].
Results
GSK phenotypic hits as ligands
The 776 GSK screening file phenotypic hits, available from the ChEMBL database (https://
www.ebi.ac.uk/chembl/) were used as input structures for target prediction using three distinct
computational approaches.Mtb targets for this set of compounds have been previously pro-
posed, where three different laboratories combined structural, historical and chemogenomic
data to predict their MoA [13]. A broad spectrum of predicted targets was proposed but no ex-
perimental validation was reported. A detailed account of the physicochemical properties and
similarity clusters of the 776 compounds has been reported previously and is not covered in
this work. However, it should be noted that more than 90% of the compounds fall within the
acceptable range for drug-like compounds [13].
Ligand and structure-based target prediction approaches
Two ligand-based methods were used to enable target prediction based solely on ligand 2D
properties in the absence of target structural information. Multiple category naïve Bayesian
classifiers (MCNBC) have been extensively applied in target prediction studies [13], [22], [21].
A second distinct method—Similarity Ensemble Approach (SEA) is widely used to predict tar-
gets based on similarities between a compound of unknown MoA and ligands sets with known
targets [26]. To complement the two ligand-based methods, we also used a structure-based ap-
proach that enables the use of available structural information of a known target to identify
compounds whose 2D molecular features are absent in known ligands and are low ranked
compounds by MCNBC and SEA. Hence, selected targets identified fromMCNBC and SEA
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were used in a structure-based strategy involving docking calculations of candidate com-
pounds, in order to investigate their binding as defined by the binding site occupancy, orienta-
tion, non-covalent bond interactions and their ligand efficiency index (LEI).
Exploring genomic space based on 2-D chemical space of ligands
A prediction algorithm was created that employed a multiple-category naïve Bayesian classifier
(MCNBC) model and the 2D ECFP_6 fingerprints [31] of compounds in the ChEMBL data-
base with pre-established inhibitory activity. Upon validation, the generated MCNBC was able
to correctly assign targets to ~93% of the compounds (Fig. 1A). These compounds had their
annotated targets assigned to rank positions 1–5 indicating high model accuracy. It is impor-
tant to note that a similar target prediction strategy was recently utilized to help suggest target-
ligand pairs for the same set of compounds active againstMtb and it had over 90% prediction
accuracy (as judged by correct target identified in the top scoring 5 predictions) in training
[13]. The main difference between this method and the version presented in this study is that
our training data consisted of human and biological target-ligand pairs; furthermore, in order
to increase the target coverage of the models, each target had at least 10 ligands, instead of the
previously reported 40 or more ligands for a given target [13]. Even though we used targets
with as few as 10 reported ligands, comparable validation results were obtained. The second
validation procedure, reported here for the first time, involved randomly splitting about 15,720
documents into 80% and 20% sets and using target-ligand pairs in the 80% document set to
train a second model—typically the boot-strapping approaches previously used do not split by
chemical series (approximated here by the reporting of congeneric series in an individual publi-
cation), we therefore consider our validation approach as more indicative of real-world appli-
cations. This way a selection of random and diverse compounds for both the training and test
sets was guaranteed. Considering the high diversity of the chemotypes in our test set, the
model achieved a satisfactory recall of 75% (Fig. 1B) upon validation. In addition to the
Table 1. Primers used in the generation of constructs pMV261::dfrA and pMV261::thyA.
Primer Sequence (5’-3’)
dfrA sense CATGCATGGATCCGATGGTGGGGCTGATCTGG
dfrA anti-sense CATGCATGAAGCTTAATCATGAGCGGTGGTAGCT
thyA sense GATCGATCGGATCCAGTGACGCCATACGAGGACCTGCTG
thyA anti-sense GATCGATCAAGCTTTCATACCGCGACTGGAGCTTTGATCGC
Restriction sites used in the cloning procedure are underlined (BamHI, HindIII)
doi:10.1371/journal.pone.0121492.t001
Fig 1. Themultiple category naïve Bayesian classifier validation results. (A) Validation results of the
model generated from randomly selected 80% target-ligand pairs and the remaining 20% was used as a test
set. (B) Validation results of the model built using target-ligand pairs from 80% of the published articles and
the test set consisted of target-ligand pairs from the remaining 20%.
doi:10.1371/journal.pone.0121492.g001
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aforementioned validation approaches, the “leave-one-out” cross-validation, in which each
sample was left out and a model built using the rest of the samples was used. For all the catego-
ries in the model, the calculated receiver-operator characteristic (ROC) area under the curve
(AUC) [9] score was greater than 0.7 and most models retrieved at least 80% of their ligands
within 10% retrieval of the dataset, indicating high sensitivity and specificity in assigning the
correct categories/targets. Subsequently, a final MCNBC model was generated using 100% of
the human/bacterial target-ligand pairs from ChEMBL version 17.
Ligand–based approach can involve activity profile similarity or comparison of chemical
similarity between a compound and a set of reference ligands [32]. SEA utilizes chemical struc-
tural similarity between two sets of ligands to infer protein similarity. The output is an expecta-
tion (E) value statistically derived from the sum of the Tanimoto similarity of the substructural
fingerprints of all pairs between the anti-TB compounds and sets of ligand for given targets. A
smaller statistically derived E value indicates a stronger similarity between two proteins and
hence potential targets.
Flouroquinolones, antibacterials known to inhibit DNA gyrase and topoisomerase IV
[33,34] whose target-ligand pairs were not in ChEMBL version 17 were presented to the
MCNBC model and SEA for further validation. The two ligand-based methods correctly as-
signed gatifloxacin, ofloxacin, moxifloxacin and lexofloxacin to Staphylococcus aureus topo-
isomerase IV (UniProt accession: P0C1U9). From the top five predictions using SEA,
topoisomerase IV was found in position one and E-values ranged from 2.20E-46 for moxifloxa-
cin to 2.05E-27 for lexofloxacin and ofloxacin. Using the MCNBC model, the correct known
target was in positions 1 and 2 for gatifloxacin (Z-score = 6.35) and moxifloxacin (Z-
score = 7.99) respectively, and in eighth position for ofloxacin and lexofloxacin both displaying
a Z-score of 3.63. Based on these observations, MCNBC model and SEA were therefore used to
predict targets for the 776 novel anti-tubercular compounds.
Number of predicted targets
Both MCNBC and SEA are tools that can be used to propose an ensemble or set of likely bio-
logical targets for new bioactive compounds and the results can indicate potential on-target
polypharmacology and off-target side effects of the drugs as well as phenotypic hits. Based on
the 2D chemical space, defined by ECFP_6 fingerprints [31] of each of the 776 GSK hits,
MCNBC predicted 1,462 targets, all with positive Bayesian scores (NB) and Z-scores> = 1.5,
possibly defining the bioactivity space of the compounds. The most frequent targets were for
theHomo sapiens proteins, which constituted about 90% (1313 proteins) of the predicted tar-
gets whilst bacterial proteins made up approximately 10% (146 proteins). There were a total of
25 unique proteins in our training set spanning from kinases, (e.g serine/threonine-protein ki-
nases like PknB, reductases like enoyl [acyl-carrier-protein] reductase (InhA), transcriptional
regulators (HTH-transcriptional regulator EthR) hydrolases (like Epoxide hydrolase, EphB),
that were assigned 132 compounds (S2 Fig., supporting information).Mtb drug targets were
further inferred by mapping functional data and chemical bioactivity data of all predicted tar-
gets across theirMtb orthologues based on the OrthoMCL database [35]. This approach has
been used elsewhere to identify potential pathogenic drug targets [13,36]. The final number of
identifiedMtb targets was 119 for 698 compounds (2343 target-ligand pairs) (Data is available
on request). For each compound, the predicted targets were ranked according to their Z-scores.
About 23 compounds were predicted as modulators ofMtb DHFR (UniProt accession:
P9WNX1 (previously P0A546)).
SEA assigned 36,607 target-ligand pairs for 1346 proteins, from all the organisms in
ChEMBL version 16. Most compounds were assigned to human targets (~79% of predicted
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PLOS ONE | DOI:10.1371/journal.pone.0121492 March 23, 2015 8 / 17
targets) and 13Mtb proteins were predicted. This number was increased to 110 after consider-
ing theMtb orthologues resulting in 1333 target-ligand pairs (428 compounds). In agreement
with MCNBC predictions,Mtb DHFR was one of the proteins identified to be a potential target
for 17 phenotypic hits. The two methods commonly predicted 12Mtb DHFR inhibitors.
Supporting 2-D based predictions with docking
A structure-based approach was used to identify potential ligands based on the normalized
binding score and determine the binding modes of the phenotypic hits toMtb DHFR. The en-
tire 776 anti-TB compounds were docked into the binding pocket of DHFR using the Internal
Coordinate Mechanism (ICM) method [27] and the strength of binding interactions decreased
from compound GSK1839228A (ICM score = -35.00 to GSK1452001A with ICM score of-
4.20. Eighteen compounds displayed ICM scores higher than that of cycloguanil (ICM
score> 25.00) indicating stronger binding interactions. The docked phenotypic hits were listed
in descending order of their Ligand Efficiency Index (LEI), calculated by dividing the ICM
score for each compound by the number of heavy atoms. The top 100 compounds, whose LEI
ranged from 0.78 to 1.45, (S1 Table, supporting information) were retrieved as the high ranked
docking compounds (hits) and were used in further analysis.
PredictedMtb DHFR ligands
The total number ofMtb DHFR ligands according to predictions by MCNBN and SEA was 28
(S2 Table, supporting information) and 12 of these compounds were amongst the top 100 mol-
ecules proposed by our structure-based approach (Fig. 2). Although both SEA and docking ap-
proaches recognized no common modulators, it was encouraging that the three orthogonal
methods commonly identified eleven potential inhibitors forMtb DHFR (Fig. 2, S2 Table, sup-
porting information). Out of these, eight compounds, S4, S5, S6, S8, S11, S12, S20, and S21
(S2 Table, supporting information) contain the 1,4,5,6-tetrahydro-1,3,5-triazin-2-amine
(THT) and the phenoxy-propoxyl scaffolds, present in the potent P. falciparum DHFR inhibi-
tors, cycloguanil and WR99210 [16,37]. The two scaffolds occupied important binding posi-
tions in DHFR binding pocket, and formed hydrophobic and hydrophilic interactions with the
residues. For instance, the THT moiety is known to interact with Asp27, a residue important
for activation of DHFR [37]. Molecular structures of compounds S1, S25 and S22 consist of
novel DHFR inhibitor scaffolds, which are the methoxyisoquinolin-8-yl, the substituted quino-
loin-5-amine and the quinazoline-2,4, diamine respectively. The overlap between MCNBC and
SEA consisted of compound GW351921X (Z-score = 3.14 and E-value = 2.38E-14). This com-
pound had a LEI of 0.74 and did not appear in the top 100 set from docking calculations since
the LEIs are lower than 0.78. The single overlap between MCNBC and docking predictions is a
small compound S10 (GSK747165A) made up of the methoxyphenyl substructure linked to a
phenyl ring. About 38% (8/21) of the MCNBC predicted ligands were solely suggested, SEA
had 29% (5/17) and out of the 100 docking hits, 88% (88/100) were exclusively proposed
(Fig. 2).
The structure-based approach also identified potential ligands containing chemical entities
not commonly found among DHFR inhibitors, such as methotrexate (S29), trimethoprime
(S30), cycloguanil (S31) andWR99210 (S32) [37] (S3 Fig., supporting Information).
3-Chloro-(methoxyphenyl)benzene-1, 2-diamine, (LEI = 1.45), is a small molecular weight
(248.7) compound with two substituted aromatic rings and 2-(2-phenoxyethoxy)-5-(thiophen-
3-yl)-benzamide, also displays novel chemical features and has a molecular weight of 339.41.
The third compound, GSK747165A (S10) (LEI = 1.41, Mwt = 214.26), 1-N-(4-methoxyphe-
nyl)benzene-1,2-diamine, is an analogue of 3-chloro-(methoxyphenyl)benzene-1, 2-diamine
Mycobacterial Dihydrofolate Inhibitors
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that lacks the chloro-substituent. All highly ranked potentialMtb DHFR inhibitors derived by
docking but compound 2-(2-phenoxyethoxy)-5-(thiophen-3-yl)-benzamide were tested in in
vitro experiments againstM. bovis BCG.
BRL-7940SA and BRL-10143SA inhibit mycobacterial DHFR
In recent years, whole genome sequencing (WGS) of spontaneous resistant mutants has been a
successful tool in identifying the target of various anti-tubercular compounds [38]. This tool
was used to test potential DHFR inhibitors that initially displayed MIC (BCG)< 5 μM, such as
BRL-7940SA (S5), BRL-10143SA (S12), GW369335X (S22), and GSK747165A (S10) (S2
Table, supporting information) againstM. bovis BCG. Two tetrahydro-1,3,5-triazin-2-amine
(THT) derivatives, BRL-7940SA, 5-(3-(2-(tert-butyl)phenoxy)propoxy)-4-imino-6,6-dimeth-
yl-1,4,5,6-tetrahydro-1,3,5-triazin-2-amine (THT1) (S5), and BRL-10143SA 5-(3-(2-ethylphe-
noxy)propoxy)-4-imino-6,6-dimethyl-1,4,5,6-tetrahydro-1,3,5-triazin-2-amine (THT2), (S12),
displayed inhibitory activity againstM. bovis BCG DHFR.
The MIC of THT1 was established inM. bovis BCG to be 3.6 μM. Spontaneous resistant
mutants ofM. bovis BCG were generated at 5 x MIC with a mutational frequency of 4 x 108.
WGS of one of these spontaneous resistant mutants revealed two high quality single nucleotide
Fig 2. Number of potential inhibitors ofMtb DHFR identified by the multiple category naïve Bayesian classifier (MCNBC), Similarity Ensemble
Approach (SEA) and docking calculations.
doi:10.1371/journal.pone.0121492.g002
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polymorphisms compared to the sequenced wild-typeM. bovis BCG strain and reference se-
quence. Both mutations, in thyA (W80S) and PPE5 (G476D) were detected with 100% allele
frequency. Mutations in ThyA (thymidylate synthase) have been linked to resistance against
the confirmed DHFR inhibitor, para-aminosalicylic acid (PAS) [39]. Consequently, over-ex-
pression studies of ThyA and DHFR inM. bovis BCG were performed to confirm the target of
THT1 and to determine the impact on the MIC of the remaining in silico identified compounds
(Fig. 3). There was no increase in resistance upon over-expression of DHFR or ThyA on the
negative control, isoniazid (target: InhA) (Fig. 3). Only the DHFR over-expresser strain exhib-
ited an increase in resistance when tested on the positive control, PAS as shown by the MICs
given in Fig. 3 (target: DHFR). Over-expression of DHFR on THT1 and THT2 resulted in an
increase in MIC from 3.6 μM to>28.8 μM and 2.8 μM to>33.6 μM, respectively. Conversely,
the ThyA over-expresser strain did not give any resistance to THT1 (MIC 3.6 μM) for both
ThyA over-expresser and empty vector, and gave increased sensitivity to THT2 from 2.8 μM
to<1.4 μM.
Fig 3. Impact on the MIC of THT1 and THT2 upon the over-expression of ThyA and DHFR with Isoniazid (INH) and para-aminosalicylic acid (PAS)
as negative and positive controls. The MICs of THT1 and THT2 were determined inM. bovis BCG containing pMV261, pMV261::thyA and pMV261::dfrA.
Plates are shown at 0.5, 1.0, 4.0 and 8.0 x MIC of each compound (with respect to the empty vector), the structures of which are given along with the IUPAC
nomenclature for THT1 and THT2 and tabulated MIC data.
doi:10.1371/journal.pone.0121492.g003
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Discussion and Conclusion
Chemogenomics approaches have provided fast and cheap utilization of the chemical and ge-
nomic space in identification of target-ligand pairs that were confirmed by using WGS meth-
ods, followed by over-expression of ThyA and DHFR inM. bovis BCG. To our knowledge, this
is the first time computationally predicted mycobacterial target-ligand pairs have been pheno-
typically validated. Compounds S4 and THT2 (S12) have been reported to potentially modu-
late the folate pathway [13]. Here, compounds THT1 (S5) and THT2 (S12) have been
confirmed to target mycobacterial DHFR. Three distinct, yet complementary, in silicomethods
independently predicted the two compounds.
In docking calculations involvingMtb DHFR, the two compounds have similar orientation
in the binding pocket (Fig. 4A), similar to the binding modes of cycloguanil (Fig. 4B), metho-
trexate, trimethoprim and Br-WR99210 previously reported [37]. The THT moiety in THT1
(brown sticks) and THT2 (yellow sticks) occupied the inner hydrophobic binding site bordered
by, amongst other residues, Phe31 and forms H-bonds with Ile5 and Asp27 and Ile94 as well as
hydrophobic interactions (Fig. 5). The ortho-substituted phenyl ring occupies the outer hydro-
phobic binding site close to the entrance of the pocket and form van der Waals forces (London
forces) with these residues with residues Gly18, Ile20, Thr46, Ser49, and Leu50 (Fig. 5). In this
site there are differences in orientation where the phenyl ring in THT1 is drawn closer to Il320
and closest distance between them is ~3.50 Å, whilst the tert-butyl fragment interacts more
with Leu50 (Fig. 5A). In contrast, the ethyl-phenyl- moiety of THT2 is closer to Leu50 (closest
distance ~3.49 Å) and there is minimum contact with Ile20 (Fig. 5B). Largely, both molecules
are stabilized by hydrophobic and polar interactions.
DHFR is essential for the production of tetrahydrofolate [16] that is crucial for the synthesis
of DNA and proteins. Inhibition of this enzyme could lead to cell death and therefore inhibit
the growth ofMtb. It is important to note that THT2 was also predicted to target InhA, Phenyl-
alanine–tRNA ligase alpha subunit, and Fibronectin-binding protein C. On the other hand
THT1 was also predicted to target dihyropteroate synthase 1 (DHPS) and Phenylalanine—
tRNA ligase alpha subunit. In our predictions theMtb DHFR was inferred from its orthologous
genes that included DHFR fromHomo sapiens, Bacillus anthracis, Escherichia coli, Lactococcus
lactis, Staphylococcus aureus, Neisseria gonorrhoeae and Lactobacillus casei. Therefore, orthol-
ogy proved to be a significant tool that can be used to link a known drug target with a potential
novel target [36].
Clearly, following chemogenomic approaches to predict a given compound’s molecular tar-
gets has the potential to reveal alternative ligands for existing targets forM. tuberculosis infec-
tion and other diseases. Such approaches can also suggest new targets for new drugs and de-
Fig 4. Bindingmode of BRL-7980SA (THT1) and BRL-10143SA (THT2). (A) Grey defines the molecular
surface and the cartoon represents the secondary structure ofMtbDHFR. Sticks represent bonds and atoms
of THT1 (brown), THT2 (yellow) and the binding pocket residues within a radius of 5 Å from the ligand. (B) A
comparison of binding mode of THT1 and cycloguanil (green).
doi:10.1371/journal.pone.0121492.g004
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convolute their adverse drug reactions (ADR). Nevertheless, the limitations of using such mod-
els based on the ChEMBL database include the fact that, in general, the predictions do not dis-
tinguish between agonists/activators or antagonists/inhibitors; however, the activities of the
compounds have been confirmed through experimental validation. In the absence of such cor-
roboration, activities can be inferred based on the predicted targets and compound structure.
Additionally, since both the MCNBC and SEA target prediction models are trained on the
ChEMBL database of known target-ligand pairs, all predicted targets are biased towards previ-
ously studied and reported proteins. Thus, this method is not able to predict directly new, un-
precedented, protein targets in biological pathways that haven’t been thoroughly studied and
added to the ChEMBL database. This limitation is however overcome by the recurrence of al-
ready validated targets, but with distinct and novel chemotypes from phenotypic screening
studies coupled with the consideration of predictedMtb protein orthologues and in vitro
validation.
The over-expression studies confirm DHFR as the target of THT1 and THT2: increased tar-
get levels enable the cells to survive in higher concentrations of drug. In the folate biosynthetic
pathway, DHFR generates tetrahydrofolates from DHF, the derivatives of which are consumed
by ThyA with the conversion of dUMP to dTMP (for DNA synthesis) and the regeneration of
DHF. This cycle ensures the replenishment of the intracellular stores of THF derivatives, which
are used in other essential single-carbon transfers. Inhibition of DHFR results in a reduced pro-
duction of THF, which is readily used by a major consumer of reduced folates, ThyA, causing a
depletion of the stores of THF (Fig. 6). Over-expression of ThyA on the DHFR-targeting com-
pounds THT2 resulted in an increased sensitivity to the compound. The increased cellular lev-
els of ThyA would cause a greater turnover of THF, the replenishment of which would be
further limited by the inhibition of native levels of DHFR in the cell by the compound. The mu-
tation in ThyA in the spontaneous resistant mutant locates to the active site. It is probable that
the mutation causes a reduction in thymidylate synthase activity. Therefore, more folates are
available for essential one-carbon additions. ThyX is a functional analogue of ThyA [39]. ThyX
bypasses the ThyA/DHFR pathway and is involved in de novo thymidylate synthesis [40] com-
pensating for the reduced activity of ThyA.
Therefore three different but complimentary computational methods were used to identify
inhibitors ofM. bovis DHFR. Two out of eight compounds (giving a hit rate of 25%) were con-
firmed using in vitroWhole Genome Sequencing experiments. This work provides two inhibi-
tors, THT1 and THT2 that can be modified into selectivemycobacterium DHFR inhibitors or
used as chemical probes in biological systems.
Fig 5. Interactions of (A) THT1 and (B) THT2 with binding pocket residues in DHFR.Residues in close
contact and interacting through hydrophobic interactions are shown in red and H-bonds (green dots) and their
distances are in green. Black lines depict residues forming polar contacts with the ligand.
doi:10.1371/journal.pone.0121492.g005
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Supporting Information
S1 Fig. Crystal structure ligand conformation was regenerated (RMSD = 0.3 Å, binding
score = -25.79 kcal/mol and LEI = 1.5).
(TIF)
S2 Fig. Examples of potentialMtb targets predicted by MCNBC. A total of 25 proteins were
assigned 132 compounds, each had Bayesian Score> = 1.0 and Z-score> = 1.5.
(TIF)
S3 Fig. Examples of DHFR inhibitors.
(TIF)
S1 Table. Docking results showing the top 100 compounds. The compounds are listed in
descending order of LEI.
(PDF)
Fig 6. The biochemical relationship between ThyA and DHFR. Enzymes are highlighted in blue. ThyA, thymidylate synthase; DHFR, dihydrofolate
reductase; SHMT, serine hydroxymethyltransferase; DHF, dihydrofolate; THF, tetrahydrofolate; mTHF, methyl tetrahydrofolate.
doi:10.1371/journal.pone.0121492.g006
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S2 Table. PredictedMtb dihydrofolate reductase ligands predicted by MCNBN, SEA and
Docking.
(PDF)
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